Medicare Negotiation and Competitive Licensing Act of 2019

HB 1046 Medicare Negotiation and Competitive Licensing Act of 2019

US Congress 116th Congress

Medicare Negotiation and Competitive Licensing Act of 2019
HB-1046


About HB-1046

Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.) The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities. Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

  

Bill Texts

Introduced 02/20/2019

Weigh In

No votes yet!
Cast yours now to be the first.

Votes for: 0 Votes against: 0

Sponsors (128)

Sponsors by party

  

Bill Sponsors

History

Subcommittee Hearings Held.

09/25/2019

Referred To The Subcommittee On Health.

02/08/2019

Introduced In House

02/07/2019

Referred To The Committee On Energy And Commerce, And In Addition To The Committee On Ways And Means, For A Period To Be Subsequently Determined By The Speaker, In Each Case For Consideration Of Such Provisions As Fall Within The Jurisdiction Of The Committee Concerned.

02/07/2019

Referred To The Subcommittee On Health.

02/07/2019